Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

BACKGROUND: Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta((1-42/1-40)), glial fibrillary acidic protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Verberk, Inge M. W., Thijssen, Elisabeth, Koelewijn, Jannet, Mauroo, Kimberley, Vanbrabant, Jeroen, de Wilde, Arno, Zwan, Marissa D., Verfaillie, Sander C. J., Ossenkoppele, Rik, Barkhof, Frederik, van Berckel, Bart N. M., Scheltens, Philip, van der Flier, Wiesje M., Stoops, Erik, Vanderstichele, Hugo M., Teunissen, Charlotte E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523295/
https://www.ncbi.nlm.nih.gov/pubmed/32988409
http://dx.doi.org/10.1186/s13195-020-00682-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523295/
https://www.ncbi.nlm.nih.gov/pubmed/32988409
http://dx.doi.org/10.1186/s13195-020-00682-7

Ejemplares similares